FEDERAL COURT OF AUSTRALIA
Gensco Laboratories, LLC v Care A2 Plus Pty Ltd (receiver appointed) [2023] FCA 1024
File number(s): NSD 560 of 2023 Judgment of: HALLEY J Date of judgment: 28 August 2023 Catchwords: PRIVATE INTERNATIONAL LAW – interlocutory application by first and third respondents for the grant of an anti-suit injunction to restrain applicants from commencing or further pursuing proceedings in the Circuit Court of the Eleventh Judicial Circuit in and for Miami-Dade County, Florida – whether necessary to protect the Court’s own processes or to restrain unconscionable conduct or unconscientious exercise of legal rights – where common and overlapping considerations involved – interlocutory application dismissed Legislation: Competition and Consumer Act 2010 (Cth) Sch 2, (Australian Consumer Law), s 236 Cases cited: CSR Limited v Cigna Insurance Australia Limited (1997) 189 CLR 345; [1997] HCA 33
Grundt v The Great Boulder Proprietary Gold Mines Limited (1937) 59 CLR 641; [1937] HCA 58
Kraft Foods Group Brands LLC v Bega Cheese Limited [2018] FCA 549
Morris v McConaghyAustralia Pty Ltd (No 3) [2018] FCA 606
Sunland Waterfront (BVI) Ltd v Prudentia Investments Pty Ltd [2013] VSCA 237
TS Production LLC v Drew Pictures Pty Ltd and Another (2008) 172 FCR 433; [2008] FCAFC 194
Division: General Division Registry: New South Wales National Practice Area: Commercial and Corporations Sub-area: Commercial Contracts, Banking, Finance and Insurance Number of paragraphs: 75 Date of hearing: 17 August 2023 Counsel for the Applicants: Ms E Bathurst Solicitor for the Applicants: King & Wood Mallesons Counsel for the First and Third Respondents: Mr G Drew Solicitor for the First and Third Respondents: Piper Alderman Counsel for the Second and Fourth Respondents: The second and fourth respondents did not appear ORDERS
NSD 560 of 2023 BETWEEN: GENSCO LABORATORIES, LLC (DOING BUSINESS AS GENSCO PHARMA)
First Applicant
GENSCO NUTRITION LLC.
Second Applicant
AND: CARE A2 PLUS PTY LTD (ABN 98 631 178 115) (RECEIVER APPOINTED)
First Respondent
AUSMORE DAIRY PTY LTD (ACN 657 054 478)
Second Respondent
KERRY HYLAND (and another named in the Schedule)
Third Respondent
ORDER MADE BY:
HALLEY J
DATE OF ORDER:
28 AUGUST 2023
THE COURT NOTES THAT:
A.The applicants have given an undertaking to the Court that they will not commence proceedings against Ms Kerry Hyland in the United States of America while Federal Court of Australia proceedings NSD 560 of 2023 are on foot against her.
THE COURT ORDERS THAT:
1.Order 6 of the orders made on 11 August 2023, as extended by Order 2 of the orders made on 17 August 2023, is to be discharged.
2.The interlocutory application filed by the first and third respondents on 11 August 2023 (Application), is to be dismissed.
3.The first and third respondents are to pay the applicants’ costs of and incidental to the Application.
4.Orders 1, 2 and 3 of these orders be stayed until 6.00 pm on Tuesday, 29 August 2023.
Note: Entry of orders is dealt with in Rule 39.32…
Keep reading for free
Create a free CaseChat account to read Gensco Laboratories, LLC v Care A2 Plus Pty Ltd (receiver ap... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2023] FCA 1024
- Decision Date
CaseChat Overview and Summary
The central legal issue for the court was whether an anti-suit injunction should be granted to restrain the applicants from pursuing the anticipated Florida proceedings. The court was required to determine if the injunction was necessary to protect the integrity of the Court's processes or to restrain unconscionable conduct. The respondents argued that the injunction was necessary due to overlapping considerations, including the potential for conflicting evidence and the inconvenience of parallel proceedings.
In dismissing the application, the court held that the respondents had not demonstrated that an anti-suit injunction was necessary to protect the integrity of the Court or to restrain unconscionable conduct. The court rejected the notion that the anticipated Florida proceedings were intended to harass the officers and directors of Care A2. Furthermore, while acknowledging the potential for overlapping evidence and witnesses, the court found that the extensive pleading in the Florida proceedings and the election for a jury trial might mitigate the risk of conflicting outcomes. Consequently, the court discharged the existing injunction, dismissed the interlocutory application, and ordered the respondents to pay the applicants' costs.
In summary, the court's decision underscored the importance of demonstrating a clear need for an anti-suit injunction, particularly where there is a risk of overlapping proceedings. The court's findings highlighted the necessity for compelling evidence of unconscionability or a significant risk to the integrity of the Court's processes to justify such an injunction.
Orders
Orders of the court
1. Order 6 of the orders made on 11 August 2023, as extended by Order 2 of the orders made on 17 August 2023, is to be discharged.
2. The interlocutory application filed by the first and third respondents on 11 August 2023 (Application), is to be dismissed.
3. The first and third respondents are to pay the applicants’ costs of and incidental to the Application.
4. Orders 1, 2 and 3 of these orders be stayed until 6.00 pm on Tuesday, 29 August 2023.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Sixth, Gensco submits that there can be no suggestion that the bringing of the Australian Proceedings constituted an election not to proceed with another claim in another jurisdiction, thus giving rise to an estoppel by conduct such that it would be unconscionable for that other claim to be pursued. It submits that there is no evidence that the commencement of the Australian Proceedings caused the respondents to the Australian Proceedings or the different defendants to the Anticipated Florida Proceedings to assume that no other proceedings would ever be brought in another jurisdiction. Rather it submits, that Gensco’s Florida counsel warned the different defendants of the potential of the Anticipated Florida Proceedings on 6 June 2023, before the commencement of the Australian Proceedings. F. CONSIDERATION The “necessary to protect integrity” and “unconscionable conduct” limbs in CSR are distinct but whether either limb is enlivened often involves common or overlapping considerations. In my view, the Care A2 respondents have not established that the interim anti-suit injunction should remain in place or that any anti-suit injunction should be granted by way of final relief with respect to the Anticipated Florida Proceedings. I do not accept that the grant of an anti-suit injunction is necessary to protect the integrity of this Court and its processes or to restrain any unconscionable conduct or unconscientious exercise of legal rights by Gensco Pharma. First, I do not accept that I should infer, that because the applicants commenced the Australian Proceedings in this country, that the purpose of the Anticipated Florida Proceedings is to harass the officers and directors of Care A2 with the cost and inconvenience of defending or appearing as witnesses in parallel proceedings. The reliance by the Care A2 respondents on Morris is misconceived. In that case, the Court was able to draw such an inference because of, inter alia, (a) a statement in an email that “I suggest we keep pushing him to have to spend funds”, (b) the party that had commenced the Hong Kong proceeding was not domiciled in the Hong Kong Special Administrative Region, and (c) the extremely brief nature of the indorsement on the writ in the Hong Kong proceeding suggested little effort had been put into it: at [19]. There is no equivalent statement in the evidence that was adduced before me at the hearing on 17 August 2023. Gensco Pharma is domiciled in Florida and the Draft Complaint is extensively pleaded. Second, I accept that there is likely to be a substantial overlap in the evidence deployed in the Australian Proceedings and the Anticipated Florida Proceeding given the common factual background to the two proceedings. Further, I accept, given the number of references to Mr Bugno, Mr Loader and Mr Galati in the SOC in the Australian Proceedings, that it is likely that each will ultimately be required to give evidence in both proceedings. I note that to some extent, the risk of conflicting credit and other findings might be expected to be reduced because the applicants have elected in the Draft Complaint for a jury trial in the Anticipated Florida Proceedings.